The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice

• Published in: Naunyn-Schmiedeberg's archives of pharmacology 2024, Vol.397 (1), p.599-616
• Main Authors: Salman, Hayder Ridha, Al-Zubaidy, Adeeb Ahmed, Abbas, Alaa Hamza, Zigam, Qassim A.
• Format: Article
• Language: English
• Subjects: Anti-inflammatory agents; Biomedical and Life Sciences; Biomedicine; Chemokines; Chemotaxis; Cytokines; Gemifloxacin; Imiquimod; Immunomodulation; Inflammation; Leukocytes (eosinophilic); Leukocytes (neutrophilic); Metastases; Neurosciences; NF-κB protein; Pharmacology/Toxicology; Propionic acid; Psoriasis; Skin diseases; Transforming growth factor-b1; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 0028-1298; 1432-1912
• DOI: 10.1007/s00210-023-02629-9

Psoriasis is a lifelong immune-driven skin condition characterized by excessive epidermal overgrowth and inflammatory cell infiltration. Gemifloxacin is a fourth-generation fluoroquinolone with improved immunomodulatory and anti-inflammatory properties that are believed to possess an attractive role in psoriasis via suppressing the production of cytokines, chemokines, and eosinophil and neutrophil chemotaxis. The aim of this research is to investigate the ameliorative effects of prolonged topical gemifloxacin (GMF) alone and combined with clobetasol propionate (CLO) on an imiquimod (IMQ)-induced mouse model of psoriasis. Forty-eight Swiss albino mice were divided into six groups of eight. All groups except the negative controls got 62.5 mg of IMQ 5% topically for 8 days. Mice in the control group (controls) got Vaseline instead. Following the induction in the IMQ 5% group, mice in treatment groups CLO 0.05, GMF 1%, GMF 3%, and CLO + GMF obtained clobetasol propionate 0.05%, GMF 1% and 3%, and a combination of both, respectively, for an additional 8 days, rendering the experiment 16 days long. Our results revealed that gemifloxacin alleviated erythematous, thickened, and scaly psoriatic lesions and inhibited the tissue level of inflammatory cytokines, including interleukin (IL)-8, IL-17A, IL-23, tumor necrosis factor-α (TNF-α), and transforming growth factor-β1 (TGF-β1). The anti-inflammatory effect also occurred by hindering nuclear factor-kappa B (NF-κB) signaling and reversing histopathological problems. Gemifloxacin acts effectively in mitigating psoriasis-associated lesions and restricting NF-κB-mediated inflammation, recommending gemifloxacin as a promising adjuvant candidate for additional studies on the long-term treatment of autoimmune and autoinflammatory dermatoses like psoriasis. Graphical abstract